Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a group, NOACs significantly reduce stroke, intracranial hemorrhage, and mortality, with lower to similar major bleeding rates compared with warfarin. All NOACs are dependent on the kidney for elimination, such that patients with creatinine clearance <25 ml/min were excluded from all the pivotal phase 3 NOAC trials. It therefore remains unclear how or if NOACs should be prescribed to patients with advanced chronic kidney disease and those on dialysis. The authors review the current pharmacokinetic, observational, and prospective data on NOACs in patients with advanced chronic kidney disease (creatinine clearance <30 ml/min) and those on dialysis. The authors frame the evidence in terms of risk versus benefit to bring greater clarity to NOAC-related major bleeding and efficacy at preventing stroke specifically in patients with creatinine clearance <30 ml/min. (J Am Coll Cardiol 2016;67:2888-99) 
(NOACs) because these drugs are at least as effective as warfarin, are safer, do not require routine monitoring, and are simpler to use (1) (2) (3) (4) (5) . advanced CKD or ESRD (8) . Despite these recommendations and the lack of prospective trials to validate the efficacy and safety of NOACs in this patient population, the prescription of these drugs is becoming more prevalent, as we showed in our previous publication (9) . Our updated analysis, as of October 2015 (unpublished data from Fresenius Medical Care), indicates that 23.5% of patients with advanced CKD and 11.6% of those on dialysis with AF who are anticoagulated were prescribed NOACs (Central Illustration). Among the NOAC-treated patients with CKD (n ¼ 102,504), the most commonly used drug was apixaban (10.4%), followed by rivaroxaban (9.5%), dabigatran (3.5%), and edoxaban (0.1%). Among the NOAC-treated dialysis patients (n ¼ 140,918), the most commonly used drug was apixaban (10.5%), followed by rivaroxaban (0.8%), dabigatran (0.3%), and edoxaban (0.01%).
This review summarizes the available evidence regarding the efficacy (prevention of stroke) and safety (major bleeding) of the 4 currently available NOACs (apixaban, rivaroxaban, dabigatran, and edoxaban), with particular emphasis on the outcomes in subgroups of patients with AF with CKD. Pharmacokinetic (PK) data for patients with advanced CKD and those on dialysis will be discussed, as well as the data on reversal agents. Finally, we outline the steps required to determine if NOACs are appropriate treatment options in patients with AF with advanced CKD or on dialysis.
RENAL PHARMACOKINETICS OF ANTICOAGULANT AGENTS
Uremia affects every organ system in the body and influences the pharmacokinetics of many drugs. Uremia can impair plasma protein binding, which may lead to increased free drug levels in the blood, and in turn, renal failure can also impair nonrenal drug metabolism by reduction and hydrolysis reactions (10, 11) .
Renal elimination of drugs occurs predom- Anticoagulant drug dosing in patients with renal impairment is based on glomerular filtration rate, which is impractical to measure directly in an office setting. Instead, the glomerular filtration rate can be estimated by measuring the 24-h urine CrCl, because almost all creatinine is eliminated through the glomerulus. Because collecting urine for 24 h is a tedious process, CrCl is typically estimated by an equation, using a single serum creatinine measurement.
For NOAC dosing, CrCl should be calculated using the Cockcroft-Gault formula, because the pivotal phase 3 NOAC trials have reported outcomes by CrCl using that formula (12) . This is despite the fact that the Cockcroft-Gault formula can overestimate true
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Chan et al. Prevalence of nonvitamin K-dependent oral anticoagulant agent (NOAC) use is rising among patients with advanced chronic kidney disease (CKD) and those on dialysis anticoagulated for atrial fibrillation, despite the most recent American Heart Association, American College of Cardiology, and European Heart Rhythm Society guideline, which discourages the use of NOACs when creatinine clearance (CrCl) is <30 ml/min. There are few randomized trial data on NOACs in this population. All NOACs depend on the kidney for elimination, and it is unclear if severe renal impairment leads to drug bioaccumulation to precipitate inadvertent bleeding. with patients on warfarin without renal disease ( Table 1 ) (17).
NOACs
Currently, there are 4 FDA-approved NOACs for stroke prevention in patients with AF: apixaban, rivaroxaban, dabigatran, and edoxaban. Table 2 summarizes the renal clearance, effect of dialysis, and reversal agents for these medications; in addition, it outlines the hazard ratios (HRs) for stroke and bleeding from the pivotal phase 3 trials among subjects with CrCl <50 ml/min (referent to warfarin). per day and with a 2.5-mg twice-daily dose in patients with 2 of the following: serum creatinine between 1.5 and 2.5 mg/dl, age $80 years, and body weight #60 kg. In the original labeling, the drug was not recommended for patients with CrCl <25 ml/min.
The drug label was amended in January 2014 for patients with renal impairment, including those with ESRD maintained on hemodialysis. For these patients, no dose reduction (5 mg twice daily) was suggested unless patients were also $80 years of age or had body weight #60 kg, in which case the reduced dose of 2.5 mg twice per day could be used. Patients with creatinine >2.5 mg/dl, with CrCl <25 ml/min, or on long-term dialysis were excluded from the ARISTOTLE trial; therefore, these dosing suggestions were based partially on a single-dose (not multidose) PK study in 8 hemodialysis subjects matched to 8 subjects with normal renal function (26) . In this study, the post-hemodialysis administration of 5 mg apixaban resulted in 36% higher drug exposure compared with healthy subjects with normal renal function. In another 10-mg single-dose PK study of 24 subjects with mild and moderate CKD compared with 8 subjects with normal kidney function, total apixaban exposure was estimated via regression models to be 44% greater in subjects with CrCl of 15 ml/min than in subjects with normal kidney function (27) .
Thus, under current dosing suggestions on the apixaban label, patients with advanced and end-stage kidney disease could be exposed to 40% more drug.
Further studies are needed to establish the optimal apixaban dose in this population.
In terms of dialysis clearance, only 6.7% of apixaban is cleared by a 4-h hemodialysis session (34, 35) . This is in contrast to another study that found a 6-fold increase in dabigatran exposure in patients with CrCl <30 ml/min compared with healthy subjects (33) . Edoxaban is poorly cleared by dialysis: 4 h of hemodialysis decreased total drug exposure by only 9% (F180NR, blood flow rate 350 ml/min, dialysate flow rate 500 ml/min) (40) .
SHOULD WE ANTICOAGULATE PATIENTS WITH AF WITH ADVANCED OR END-STAGE KIDNEY DISEASE TO PREVENT STROKE?
Patients with AF with advanced CKD or on dialysis are at high risk for adverse events and are complicated to manage. Most of these patients will have CHA 2 DS 2 -VASc scores >2, and studies indicate that the rates of AF, stroke, and bleeding all increase as kidney function worsens (25) . There are no prospective randomized studies on the efficacy and safety of anticoagulation to prevent stroke in this population. NOACs in Advanced CKD and Dialysis J U N E 2 1 , 2 0 1 6 : 2 8 8 8 -9 9
CrCl of 58 ml/min (56) . Idarucizumab is partially dependent on the kidney for elimination (32% within the first 6 h) but is approved for patients with kidney disease.
The anticoagulant effects of warfarin, apixaban, rivaroxaban, and edoxaban can be reversed by 4-factor prothrombin complex concentrate (57-59), which can replete coagulation factors much faster than fresh-frozen plasma, with less volume overload, which is favorable to patients with advanced CKD and on dialysis who are prone to volume overload (60) . High-quality randomized trials should be conducted in these populations, given their altered drug metabolism profile and high rates of both clotting and bleeding events.
